Acting FDA commissioner meets rare disease groups to improve relations

Acting FDA Commissioner Kyle Diamantas met with rare disease groups to improve relations after predecessor's actions. The groups seek more certainty and support for treatments for small patient populations, following recent FDA decisions that impacted drugmakers. This meeting aims to steady operations and address challenges in developing therapies for rare diseases, a community that previously influenced legislation.